Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Squamous Cell Cancer 2Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 57Radiotherapy 35Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 24Radiation 21Carboplatin 19pembrolizumab 18Specimen Handling 16Platinum 14Cetuximab 141,2-diaminocyclohexaneplatinum II citrate 14Surveys and Questionnaires 13Paclitaxel 13Biopsy 11Surgical Procedures, Operative 10Fluorouracil 10Docetaxel 9Taxes 8Nivolumab 8Drug Therapy 8Chemoradiotherapy 8durvalumab 7Fluorodeoxyglucose F18 7Observation 6Blood Specimen Collection 6fludarabine 5X-Rays 5Immunohistochemistry 5Cyclophosphamide 5aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × Alpelisib × Head & Neck × Clear all
NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡